Carbapenems have been considered the last treatment option for infections caused by multidrug-resistant pathogens \[[@CIT0001], [@CIT0002]\]. However, their use has been compromised due to the increasing prevalence of carbapenem-resistant gram-negative bacteria, which has become a global concern \[[@CIT0001], [@CIT0002]\]. Although carba penem resistance has historically been limited to hospital-acquired infections caused by *Pseudomonas* spp. and *Acinetobacter* spp., it is now becoming more commonplace among infections caused by the *Enterobacteriaceae* family. Carbapenem-resistant *Enterobacteriaceae* spp. (CRE) can cause a range of hospital- acquired infection types, with bloodstream infections (BSIs), hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), intra-abdominal infections (IAIs), and urinary tract infections (UTIs) being the most common \[[@CIT0003]\]. As a testament to the seriousness of this emerging antibiotic-resistant pathogen, the Centers for Disease Control and Prevention published a report in 2013 outlining the top 18 drug-resistant threats to the United States, of which CRE was 1 of 3 pathogens categorized as an urgent threat.

Despite increased appreciation of CRE, the outcomes associated with it have not been well described. There have been a number of attempts in the literature to characterize the outcomes associated with CRE, but the studies have been limited in sample size and scope. There is also a debate as to whether empiric therapy for infections due to CRE should contain 1 or more antibiotics. Because the prevalence of infections due to CRE is expected to increase, an understanding of the evidence on overall and treatment-associated outcomes in patients with these difficult-to-treat infections is required. To evaluate the available evidence in this area, a systematic literature review and meta-analysis (MA) were conducted to investigate the association between CRE and carbapenem-susceptible *Enterobacteriaceae* (CSE) infections and mortality among hospitalized adult patients.

METHODS {#s1}
=======

Systematic Literature Review {#s2}
----------------------------

Systematic searches of MEDLINE (via PubMed), Embase, and Cochrane-indexed databases were conducted to identify English-language articles published between January 1, 1994, and December 1, 2015, using keywords for carbapenem resistance that were paired with terms for the infection types of interest (BSI, HABP/VABP, IAI, and UTI). The search string for this systematic literature review included terms for the broad genus of Gram-negative bacteria included within the *Enterobacteriaceae* family. This included the term *Enterobacter,* as well as *Klebsiella*, *Serratia*, *Escherichia*, and *Citrobacter*, to ensure comprehensive identification of relevant studies (search terms are listed in [Supplementary File 1](#sup1){ref-type="supplementary-material"}). However, we did not conduct analyses by specific pathogens. The review was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CIT0004]\]. A manual check of bibliographies of recent systematic literature reviews and MAs was performed to ensure a comprehensive retrieval of literature of interest.

Study Selection {#s3}
---------------

Abstracts were reviewed and screened manually using the Patients, Interventions, Comparators, Outcomes, Study Design, and Time Period (PICOS-T) inclusion and exclusion criteria ([Table 1](#T1){ref-type="table"}). Included articles evaluated outcomes in hospitalized patients with BSI, HABP/VABP, IAI, or UTI due to CRE. Full-text articles of the references included during abstract review were obtained, reviewed, and screened by a single investigator using the same inclusion/exclusion criteria applied for abstracts. All excluded studies were confirmed by a senior investigator, with any discrepancies between the 2 investigators resolved by a third investigator.

###### 

Inclusion/Exclusion Criteria for Study Selection

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study Criteria   Patients                                                                                                                                         Interventions                       Comparators      Outcomes                                                                                    Study Design                                                                                                                                                                                                                                               Time Frame
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------- ---------------- ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Inclusion        Studies evaluating hospitalized adult patients with confirmed or suspected HABP/VABP, cUTIs, bacteremia, or cIAI attributable to CRE pathogens   All antibiotics considered          Any antibiotic   Mortality\                                                                                  Observational studies (prospective/ retrospective)\                                                                                                                                                                                                        Studies published between January 1, 1994, and December 1, 2015
                                                                                                                                                                                                                         Infection-related mortality\                                                                Randomized trials\                                                                                                                                                                                                                                         
                                                                                                                                                                                                                         Reinfection\                                                                                Nonrandomized trials                                                                                                                                                                                                                                       
                                                                                                                                                                                                                         Readmission\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                         Length of hospital stay\                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                         Length of ICU stay\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                         Any economic outcome\                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                         Adverse events                                                                                                                                                                                                                                                                                                                                         

  Exclusion        Studies evaluating patients without CRE infections\                                                                                              Treatments other than antibiotics                    Studies not reporting clinical or economic outcomes related to CRE infections of interest   Animal, in vitro, or genetic studies; narrative publications, nonsystematic reviews, case studies, case reports, and editorials; comparative studies with \<10 patients per treatment group in ≥2 treatment arms or single-arm studies with ≤20 patients   Studies published before 1994 or after December 1, 2015
                   Studies not reporting separable outcomes for patients with HABP/VABP, cUTIs, bacteremia, or cIAI\                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                   Studies evaluating pediatric patients\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                   Studies of patients with community- acquired infections\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                   Studies evaluating patients treated in the outpatient setting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: cIAI, complicated intra-abdominal infection; CRE, carbapenem-resistant *Enterobacteriaceae*; cUTI, complicated urinary tract infection; HABP/VABP, hospital-acquired and ventilator-associated bacterial pneumonia; ICU, intensive care unit.

Data Extraction {#s4}
---------------

Data extraction was performed on studies included after full-text review using a template developed in Excel (Microsoft Corporation, Redmond, WA) that contained the data elements planned for capture (data elements planned for capture are listed in [Supplementary File 2](#sup1){ref-type="supplementary-material"}). Study-level data, patient characteristics, treatment details, and outcomes were extracted as available from all included articles by a single investigator and then validated by a second investigator to confirm the completeness and accuracy of extraction. Any discrepancies between the 2 investigators were resolved by a third investigator.

Meta-analyses {#s5}
-------------

Using a random-effects model, frequentist MAs of the odds ratios (ORs) for mortality were conducted by using data extracted or calculated from each study. Heterogeneity, the differences between the results of the compared studies after accounting for sampling error, was quantified using the Cochran Q and the *I*^*2*^ measures \[[@CIT0005]\].

Statistical Analyses {#s6}
--------------------

Statistical analyses were conducted using the R 2.15.2 statistical software program (metafor Package, Wolfgang Viechtbauer, GNU General Public License Version 2; [http://www. m etafor-project.org/doku.php](http://www.metafor-project.org/doku.php)). Data for overall mortality were analyzed using 30-day or in-hospital mortality; for studies that reported mortality at multiple time points, the latest time point was used (up to mortality at 90 days). Summary ORs for mortality were determined for the following comparisons: CRE vs CSE infections, BSI caused by CRE vs CSE, carbapenem- resistant *Klebsiella pneumoniae* (CRKP) vs carbapenem- susceptible *K. pneumoniae* (CSKP) infections, *K. pneumoniae* carbapenemase (KPC)--producing CRE vs non-KPC- producing CSE infections, and monotherapy vs combination therapy in CRE infections.

RESULTS {#s7}
=======

Systematic Literature Review {#s8}
----------------------------

Of the 1260 references identified from the literature searches, 227 were obtained in full text for further review ([Figure 1](#F1){ref-type="fig"}). After review of the 227 full-text citations, 194 articles were rejected and 33 met the criteria for inclusion. The primary reasons for rejection were that the articles were not specific to patients with CRE infections (75/194; 38.7%) or outcomes were not reported separately for the population of interest (64/194; 33.0%). Four additional studies were identified through the manual bibliography review process, resulting in a total of 37 studies that were identified for inclusion in the review and eligible for extraction. Of the 37 identified studies, 22 reported data that met criteria for inclusion in the MA ([Table 2](#T2){ref-type="table"}) \[[@CIT0006]\].

###### 

Studies Included in the Analyses

  Author, Year                                   Study Design                 Indication           Pathogen          Susceptibility        n/N       Mortality Rate, %
  ---------------------------------------------- ---------------------------- -------------------- ----------------- --------------------- --------- -------------------
  Ben-David, 2012 \[[@CIT0007]\]                 Retrospective cohort study   BSI                  *K. pneumoniae*   CRE                   29/42     69.0
                                                                                                                     CSE                   20/85     23.5
  Bleumin, 2012 \[[@CIT0008]\]                   Case-control                 Mixed                *K. pneumoniae*   CRE                   38/43     88.4
                                                                                                                     CSE                   78/148    52.7
  Brizendine, 2015 \[[@CIT0009]\]                Retrospective cohort study   cUTI                 *K. pneumoniae*   CRE                   4/22      18.2
                                                                                                                     CSE                   1/64      1.6
  Chang, 2011 \[[@CIT0010]\]                     Case-control                 BSI                  *E. coli*         CRE                   16/17     94.1
                                                                                                                     CSE                   17/34     50.0
  Daikos, 2009 \[[@CIT0011]\]                    Retrospective cohort study   BSI                  *K. pneumoniae*   CRE                   6/14      42.9
                                                                                                                     CSE                   10/53     18.9
  Daikos, 2014 \[[@CIT0012]\]                    Case-control                 BSI                  *K. pneumoniae*   Combination therapy   28/103    27.2
                                                                                                                     Monotherapy           32/72     44.4
  de Oliveira, 2015 \[[@CIT0006]\]               Retrospective cohort study   Mixed                *K. pneumoniae*   Combination therapy   32/61     52.5
                                                                                                                     Monotherapy           21/57     36.8
  Giacobbe, 2015 \[[@CIT0013]\]                  Case-control                 BSI                  *K. pneumoniae*   KPC                   73/142    51.4
                                                                                                                     Non-KPC CSE           112/284   39.4
  Hussein, 2013 \[[@CIT0027]\]                   Case-control                 BSI                  *K. pneumoniae*   KPC                   45/103    43.7
                                                                                                                     Non-KPC CSE           62/214    29.0
  Kontopidou, 2014 \[[@CIT0015]\]                Retrospective cohort study   Mixed                *K. pneumoniae*   Combination therapy   8/43      18.6
                                                                                                                     Monotherapy           16/64     25.0
  Mouloudi, 2010 \[[@CIT0016]\]                  Case-control                 BSI                  *K. pneumoniae*   KPC                   15/19     78.9
                                                                                                                     Non-KPC CSE           9/22      40.9
  Ny, 2015 \[[@CIT0017]\]                        Case-control                 cUTI and Pneumonia   *K. pneumoniae*   CRE                   14/48     29.2
                                                                                                                     CSE                   7/48      14.6
  Orsi, 2013 \[[@CIT0018]\]                      Case-control                 Mixed                *K. pneumoniae*   KPC                   16/44     36.4
                                                                                                                     Non-KPC CSE           17/60     28.3
  Papadimitriou-Olivgeris, 2013 \[[@CIT0019]\]   Case-control                 BSI                  *K. pneumoniae*   KPC                   63/164    38.4
                                                                                                                     Non-KPC CSE           17/62     27.4
  Patel, 2008 \[[@CIT0020]\]                     Case-control                 Mixed                *K. pneumoniae*   KPC                   48/99     48.5
                                                                                                                     Non-KPC CSE           73/276    26.4
  Qureshi, 2012 \[[@CIT0021]\]                   Case-control                 BSI                  *K. pneumoniae*   KPC                   9/19      47.4
                                                                                                                     Non-KPC CSE           53/272    19.5
  Qureshi, 2012 \[[@CIT0022]\]                   Retrospective cohort study   BSI                  *K. pneumoniae*   Combination therapy   2/15      13.3
                                                                                                                     Monotherapy           11/19     57.9
  Schwaber, 2008 \[[@CIT0023]\]                  Case-control                 Mixed                *K. pneumoniae*   CRE                   21/48     43.8
                                                                                                                     CSE                   7/56      12.5
  Trecarichi, 2015 \[[@CIT0024]\]                Prospective cohort study     BSI                  *K. pneumoniae*   CRE                   6/13      46.2
                                                                                                                     CSE                   3/20      15.0
  Tumbarello, 2012 \[[@CIT0025]\]                Retrospective cohort study   BSI                  *K. pneumoniae*   Combination therapy   27/79     34.2
                                                                                                                     Monotherapy           25/46     54.3
  Tumbarello, 2015 \[[@CIT0014]\]                Retrospective cohort study   Mixed                *K. pneumoniae*   Combination therapy   93/291    32.0
                                                                                                                     Monotherapy           80/156    51.3
  Zarkotou, 2011 \[[@CIT0026]\]                  Case-control                 BSI                  *K. pneumoniae*   Combination therapy   0/20      0.0
                                                                                                                     Monotherapy           7/15      46.7

Abbreviations: BSI, blood stream infection; CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem-susceptible *Enterobacteriaceae;* cUTI, complicated urinary tract infection.

![Systematic literature search and review and study attrition. Abbreviations: CRE, carbapenem-resistant *Enterobacteriaceae*; RCT, randomized controlled trial. ^a^Represents 33 articles identified using electronic database search and 4 articles identified using manual reference checks.](ofy15001){#F1}

Mortality Odds Ratios {#s9}
---------------------

### CRE vs CSE Infections {#s10}

Twelve observational studies examined overall mortality in CRE vs CSE populations; 8 studies were case-control studies, and 4 were retrospective or prospective cohort studies \[[@CIT0007], [@CIT0016], [@CIT0020], [@CIT0023], [@CIT0024], [@CIT0027]\]. Of these studies, half (k = 6) included patients with BSIs, 1 included patients with complicated UTIs (cUTIs), 1 included patients with cUTI or pneumonia, and 4 included patients with a mixture of CRE infections. Most studies (83%; 10/12) evaluated patients with CRE infections attributed to *K. pneumoniae* pathogens; 1 study each assessed either carbapenem resistance due to *Escherichia coli* or mixed *Enterobacteriaceae* pathogens.

Infection with CRE was associated with a significantly higher risk of overall mortality compared with CSE (OR, 3.39; 95% CI, 2.35--4.89) ([Figure 2](#F2){ref-type="fig"}). Heterogeneity was moderate (*I*^*2*^ = 45.5%; Qp = 0.041). The lowest ORs were reported by Orsi et al. and Hussein et al. (OR, 1.51; 95% CI, 0.74--3.09; and OR, 1.90; 95% CI, 1.17--3.10, respectively) \[[@CIT0018], [@CIT0027]\]; the highest ORs were reported by Chang et al. (OR, 16.00; 95% CI, 1.90--134.54) and Brizendine et al. (OR, 14.00; 95% CI, 1.47--133.24) \[[@CIT0009], [@CIT0010]\].

![Mortality in patients with CRE vs CSE infections. Abbreviations: CI, confidence interval; CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem- susceptible *Enterobacteriaceae*.](ofy15002){#F2}

BSIs Caused by CRE vs CSE {#s11}
-------------------------

Six studies with mortality data for CRE vs CSE populations with BSIs were included in the MA \[[@CIT0007], [@CIT0010], [@CIT0011], [@CIT0016], [@CIT0024], [@CIT0027]\]. In patients with BSIs, CRE was associated with a significantly higher risk of overall mortality compared with CSE (OR, 3.65; 95% CI, 2.11--6.30) ([Figure 3](#F3){ref-type="fig"}). Heterogeneity was moderate (*I*^*2*^ = 39.5%; Qp = 0.063). The lowest OR was reported by Hussein et al. (OR, 1.90; 95% CI, 1.17--3.10) and the highest by Chang et al. (OR, 16.00; 95% CI, 1.90--134.54) \[[@CIT0010], [@CIT0027]\].

![Mortality in patients with BSIs due to CRE vs CSE. Abbreviations: BSI, blood stream infection; CI, confidence interval; CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem-susceptible *Enterobacteriaceae*.](ofy15003){#F3}

CRKP vs CSKP Infections {#s12}
-----------------------

Eleven studies were identified for the analysis of studies of infections caused by CRKP vs CSKP \[[@CIT0007], [@CIT0011], [@CIT0016], [@CIT0020], [@CIT0023], [@CIT0024], [@CIT0027]\]. Infection with CRKP was associated with a significantly higher risk of overall mortality compared with CSKP (OR, 3.22; 95% CI, 2.26--4.57) ([Figure 4](#F4){ref-type="fig"}). Heterogeneity was moderate (*I*^*2*^ = 42.4%; Qp = 0.057). The lowest ORs were reported by Orsi et al. (OR, 1.51; 95% CI, 0.74--3.09) and Hussein et al. (OR, 1.90; 95% CI, 1.17--3.10) and the highest by Brizendine et al. (OR, 14.00; 95% CI, 1.47--133.24) \[[@CIT0009], [@CIT0018], [@CIT0027]\].

![Mortality in patients with infections caused by CRKP vs CSKP. Abbreviations: CI, confidence interval; CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem-susceptible *Enterobacteriaceae*; CRKP, carbapenem-resistant *Klebsiella pneumoniae*; CSKP, carbapenem-susceptible *K. pneumoniae*.](ofy15004){#F4}

KPC-Producing CRE vs Non-KPC-Producing CSE Infections {#s13}
-----------------------------------------------------

All 7 studies in patients with KPC-producing CRE vs non-KPC-producing CSE infections were case-control \[[@CIT0013], [@CIT0016], [@CIT0018], [@CIT0027]\]. Five studies (71%) included patients with BSIs; 2 studies included patients with a mix of infection types. Infection with KPC-producing CRE was associated with a significantly higher risk of overall mortality compared with non-KPC-producing CSE infections (OR, 2.03; 95% CI, 1.60--2.57) ([Figure 5](#F5){ref-type="fig"}). Heterogeneity was low (*I*^*2*^ = 8.9%; Qp = 0.368). The lowest OR was reported by Orsi et al. (OR, 1.59; 95% CI, 0.70--3.64) and the highest by Mouloudi et al. (OR, 5.42; 95% CI, 1.35--21.80) \[[@CIT0016], [@CIT0018]\].

![Mortality in patients with KPC-producing CRE vs non-KPC-producing CSE infections. Abbreviations: CI, confidence interval; CRE, carbapenem-resistant *Enterobacteriaceae*; CSE, carbapenem-susceptible *Enterobacteriaceae*; KPC, *Klebsiella pneumoniae* carbapenemase.](ofy15005){#F5}

Monotherapy vs Combination Therapy for CRE Infections {#s14}
-----------------------------------------------------

Seven studies included in the analysis compared monotherapy with combination therapy for CRE; 5 were considered retrospective, and 2 were case-control \[[@CIT0006], [@CIT0012], [@CIT0014], [@CIT0015], [@CIT0021], [@CIT0025], [@CIT0026]\]. Four of the studies included patients with BSIs, and 3 studies included patients with a mix of infection types attributed to CRE.

Monotherapy treatment of patients with CRE infections was associated with a significantly higher risk of overall mortality compared with combination therapy (OR, 2.19; 95% CI, 1.00--4.80) ([Figure 6](#F6){ref-type="fig"}). Heterogeneity was high (*I*^2^ = 84.2%; Qp = 0.003); de Oliveira et al. reported the lowest OR at 0.53 (95% CI, 0.25--1.10) and Zarkotou et al. the highest at 32.11 (95% CI, 1.94--531.32) \[[@CIT0006], [@CIT0026]\].

![Mortality in patients with CRE infections treated with monotherapy vs combination therapy. Abbreviations: CI, confidence interval; CRE, carbapenem-resistant Enterobacteriaceae.](ofy15006){#F6}

DISCUSSION {#s15}
==========

Two important questions arise for clinicians and public health officials when faced with the emergence of infections due to a new antibiotic-resistant pathogen like CRE. First, there is interest in understanding the incremental clinical and economic burdens associated with infections caused by a resistant pathogen relative to its susceptible counterpart. Knowledge of this is critical to ensure sufficient resource allocation across health care facilities and public agencies to manage and control these newly identified resistant infections. Second, data regarding best treatment practices, preferably from clinical studies, are needed to maximize treatment-related outcomes. The latter is particularly important among patients with infections due to CRE. Beta-lactams have historically been the drugs of choice for the treatment of infections due to *Enterobacteriaceae* spp. \[[@CIT0001]\]. Resistance to carbapenem has minimized the usefulness of the most commercially available beta-lactams and has led clinicians to use older and, in many cases, more toxic agents to treat infections due to CRE \[[@CIT0001]\].

Overall, the analyses presented here document the increased mortality associated with serious infections caused by CRE relative to CSE infections among adults in the hospital setting. Results show that patients with carbapenem-resistant infections attributable to *Enterobacteriaceae* pathogens are approximately 3 times more likely to die than patients with infections that are susceptible to carbapenems. This association was consistently found in subgroup analyses of patients with BSI only and in infections caused by *K. pneumoniae*. Similar results were found in an analysis of patients with KPC-producing infections, where point estimates show that patients are twice as likely to die compared with patients with non-KPC carbapenem- susceptible infections. Analysis of 30-day mortality, limited to BSIs, yielded nearly identical results on mortality risk. These results align with the results of another antibiotic-resistant vs antibiotic-susceptible comparator study, which demonstrated a 2-fold increase in mortality among the CRE group relative to the CSE group \[[@CIT0028]\]. Collectively, these findings highlight the need for expanding therapeutic options, refining infection management, and identifying risk factors for worse outcomes in patients with CRE infections.

The observed differences in mortality may be due to organism-, patient-, and treatment-related factors. Consistent with other infections due to antibiotic-resistant pathogens, patients with CRE tend to have a greater disease severity and more comorbid conditions relative to patients with infections due to CSE \[[@CIT0001]\]. As in most meta-analyses, we relied on the unadjusted bivariate findings across the included studies as data inputs. Although this approach obscures our ability to discern the proportion of CRE-related outcomes attributable to patient-related factors, 5 of the 7 studies in which multivariate analyses were used to adjust for baseline characteristics and conditions indicated that the presence of CRE remained a significant predictor of mortality \[[@CIT0007], [@CIT0011], [@CIT0016], [@CIT0020], [@CIT0023]\]. Thus, overall findings from the meta-analysis and the multivariate findings across the included studies indicate that the differences in mortality between patients with infections due to CRE and CSE are possibly due to treatment- or organism-related factors rather than differences in study population baseline characteristics. However, further studies are needed to clarify the definitive reasons for higher mortality among patients with infections due to CRE vs CSE.

Several treatment-related factors provide a plausible explanation for the greater mortality incurred among patients with infections due to CRE vs CSE. The studies included in this meta-analysis demonstrated that patients with CRE are at an increased risk for delayed administration of a microbiologic active antibiotic \[[@CIT0007], [@CIT0009], [@CIT0011], [@CIT0020], [@CIT0024], [@CIT0027]\]. The high rates of delayed appropriate therapy reported across these studies are alarming because numerous investigators across various infection types and pathogens have found an association between delayed treatment and poor outcomes the risk of a poor outcome to treatment delays. In the few CRE vs CSE comparative studies included in this meta-analysis that evaluated the effect of timeliness of therapy on mortality, patients who had delays in receipt of microbiologic active therapy had higher mortality, often independent of carbapenem resistance status \[[@CIT0009], [@CIT0011], [@CIT0024], [@CIT0027]\].

Beyond the complications caused by treatment delays, differences in antibiotic treatment for CRE and CSE infections play a role in observed mortality differences. As stated previously, resistance has minimized the usefulness of most commercially available beta-lactams \[[@CIT0002]\]. Optimal treatment for serious infections due to CRE remains undefined and often involves use of tigecycline, colistin, gentamicin, and amikacin, alone or in combination with each other and carbapenems \[[@CIT0001]\]. In assessing the effect of treatments on mortality outcomes in patients with CRE infections in this meta-analysis, monotherapy led to an increased mortality risk; patients receiving just 1 antimicrobial were twice as likely to die compared with those treated with multiple CRE-active antibiotics. This risk was markedly increased in patients with BSI, where those treated with monotherapy were 3.8 times more likely to die compared with those patients receiving combination therapy. A high level of heterogeneity was noted in monotherapy vs combination therapy analyses, which was likely driven by differences in the treatments received across the monotherapy and combination therapy groups. Even in cases where patients received combination therapy, mortality rates were still 30%--50% in some patient subgroups \[[@CIT0014], [@CIT0015]\]. In addition, studies found that certain therapies, such as colistin and polymyxin, were associated with increased risk for renal adverse events, including nephrotoxicity. These findings underscore the need for effective antimicrobials with favorable safety profiles because adverse events may increase the risk of death in these patients. Given the high mortality rates in this population, these findings also highlight the need for additional treatment options to achieve more favorable outcomes in CRE infections.

Several points should be addressed when interpreting these findings. Study design limitations included those inherent with any meta-analysis, such as heterogeneity across studies that may originate from differences in study populations, different definitions of carbapenem resistance, and the lack of a multivariate control. Heterogeneity was noted in several meta-analyses. Interestingly, the studies driving the heterogeneity in the CRE vs CSE comparative analyses were mainly those that assessed cUTI, an infection type that is associated with a lower mortality rate relative to others included in this analysis. A targeted analysis taking into account all confounders was not possible, limiting the ability of this meta-analysis to definitively establish the presence of a causal relationship. Because most of the included articles were retrospective, observational cohort studies, treatment selection bias and management decisions with respect to dosage adjustments could not be analyzed, and the potential for publication bias cannot be excluded. The findings of this analysis were primarly due to differences in mortality between CRE and CSE among patients with infections due to *Klebsiella* spp. Further study is needed is needed to assess the effect of carbapenem resistance among other members of the *Enterobacteriaceae* family, including *Enterobacter* spp. This analysis did not evaluate other outcomes (eg, length of hospital stay) or assess cost-effectiveness. Data are needed to evaluate how CRE affects these outcomes. Finally, this analysis was conducted before the availability of newer antibiotics including ceftazidime avibactam and meropenem/vaborbactam.

CONCLUSIONS {#s16}
===========

Results of the analysis demonstrate the increased mortality associated with serious infections due to CRE relative to CSE infections among adults in the hospital setting. Overall results and results among subgroups of patients with BSIs, infections due to *K. pneumoniae*, and infections due to KPC-producing pathogens showed that patients with CRE have mortality rates 2- to 3-fold higher than those with infections caused by CSE. Although the exact cause of the higher mortality rates among patients with CRE remains undefined, it is likely driven by delays in receipt of early, appropriate empiric therapy. As new antibiotics and treatment paradigms become available and are more widely used, it will be important to reassess mortality in patients with infections caused by CRE and CSE.

Supplementary Data {#s17}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 
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